Skip to main content

Research Repository

Advanced Search

Dr Barbara Guinn's Recognition (49)

International Faculty, Progress in Vaccines Against Cancer (PIVAC)
2024

Description The first “Progress in Vaccination against Cancer” took place in Cambridge, UK, in 2001, at a time when many investigators were highly sceptical as to whether any progress could ever be achieved in this endeavour. However, much has changed in the intervening two decades, during which the small intimate PIVAC conferences have been held annually, missing only one year because of the COVID-19 pandemic lockdown. Hence, PIVAC #23 will be taking place in 2024, September 26–28 in Prague, Czech Republic.

It is our pleasure to invite you to present your latest data at this meeting, and to discuss progress in vaccination against cancer in the historic environs of Charles University, one Europe´s oldest.
We are looking forward to another excellent PIVAC meeting in the wonderful city of Prague next September, and sincerely we hope that you will be able to join us for this event.
Research Themes Health and Health Inequalities
Org Units Centre for Biomedicine
URL https://www.pivac-prague.cz/

Invited Speaker - Progress in Vaccines Against Cancer 2024, Prague, Czech Republic
2024 - 2024

Description The first “Progress in Vaccination against Cancer” took place in Cambridge, UK, in 2001, at a time when many investigators were highly sceptical as to whether any progress could ever be achieved in this endeavour. However, much has changed in the intervening two decades, during which the small intimate PIVAC conferences have been held annually, missing only one year because of the COVID-19 pandemic lockdown. Hence, PIVAC #23 will be taking place in 2024, September 26–28 in Prague, Czech Republic.

It is our pleasure to invite you to present your latest data at this meeting, and to discuss progress in vaccination against cancer in the historic environs of Charles University, one Europe´s oldest.
We are looking forward to another excellent PIVAC meeting in the wonderful city of Prague next September, and sincerely we hope that you will be able to join us for this event.
Org Units Centre for Biomedicine
URL https://www.pivac-prague.cz/

External referee for KWF Kankerbestrijding – Dutch Cancer Society (DCS)
2024

Description KWF Kankerbestrijding/KWF Dutch Cancer Society was founded in 1949. Back then, the prognosis for cancer patients was bleak: 5 years post-diagnosis, only 49% of the cancer patients was still alive. Nowadays, this number has increased to 68% . We thank our donors, whose generous donations has enabled researchers to detect, understand and treat cancer better.

However, despite these promising numbers, our task is not finished. The increasing complexity of oncology is accompanied by new challenges and questions. Not only for patients and doctors, but for society as a whole. If more cancer patients can be cured, or survive longer, how can we optimize their quality of life? How can we stimulate better treatment for rare and hard-to-treat tumours? And how can we prevent cancer?

The patient is key
Through our actions, we support patients in every aspect of their life. For people who have not yet been diagnosed with cancer, as well as for patients who can’t be cured.

Our main goals are:
To prevent cancer wherever we can.
To stimulate better treatment for every type of cancer.
To aim for a better quality of life for (recovered) patients and their loved ones.

To ensure that high quality palliative care is available for all patients.
Through stimulation of focused scientific research, policy making, knowledge transfer and collaboration with our stakeholders, KWF is dedicated to improving the lives of cancer patients and their loved ones. Our organisational structure enables us to respond quickly to developments in society and research. Examples include our campaign for the HPV-vaccine, which prevents HPV-related cancers. And our support for new initiatives to stimulate broader availability of cancer drugs.

There are enormous challenges ahead of us. KWF can’t face these alone. Therefore, we join forces with (inter)national stakeholders to achieve our goals. With the support of society, which includes 100,000 volunteers and almost 1 million donors.

We work together for a better life with and without cancer; this is what we stand for!

KWF Dutch Cancer Society
KWF consists of:

A Supervisory Board who supervises the policies of the administration, and the general course of events of KWF.

A board who is responsible for the general management of KWF. The board members are Carla van Gils and Dorine Manson.

The Supervisory Board consists of the following members:

Ir. Wiebe Draijerchair
Dr. Bas Leerink​
​Koos Timmermans
Drs. Mijke van Ballegooijen​
Hilde Garssen​
Michaëla Ulrici

KWF Board of Advisors
KWF Board of Advisors consists of about 100-120 experts who advise KWF on achieving its mission goals from multiple perspectives. The experts are scientists, (former) patients, volunteers, health care providers and other relevant stakeholders.
Research Themes Health and Health Inequalities
Org Units Centre for Biomedicine
URL https://www.kwf.nl/en/dutchcancersociety

Invited Speaker at PIVAC23 in Athens, Greece
2023

Description Invited Speaker at “The 22nd International Conference on Progress in Vaccination Against Cancer” (PIVAC-23) which was held from 28th –30th September 2023 in Athens, Greece at the Saint Savvas Cancer Hospital, 171 Alexandras avenue, 11522, Athens.
PIVAC 23 aims to bring together scientists working on translational and clinical cancer research for three days of presentations on the most recent advances in these fields including (i) immunotherapies (cellular, immune checkpoint blockade, vaccines); (ii) innate immunity and tumor control; (iii) host- tumor interactions in the tumor microenvironment; (iv) in vitro and in vivo models for cancer immunotherapies (v) combinational cancer therapy approaches; and (vi) prognostic and predictive biomarkers in tumors and immune cells.

Improved knowledge of genomic and molecular alterations in tumors has significantly contributed to improved clinical outcomes. However, many hurdles remain to be overcome. Alterations in the tumor genome are associated not only with immune stimulation but also with an immune suppressive microenvironment and tumor immune escape mechanisms. Currently, various promising novel approaches are being employed to improve the efficacy of immunotherapies alone or in combination with targeted therapies, often by seeking to reverse the immunosuppressive environment. Additionally, prognostic signatures are being sought in order to provide a basis for tailored immunotherapies.

During the meeting there will be plenty of time for fruitful discussions between speakers and participants to encourage the emergence of new collaborations.

On behalf of the Organizing Committee, we are pleased to invite you to participate in this Meeting.

Chair:

Olga Balaoura, President of the Board of Directors and Commander of the Saint Savvas Cancer Hospital
Dr. Constantin N. Baxevanis, Scientific Director Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savvas Cancer Hospital
George Georgiou, Deputy Director of Finance, Saint Savvas Cancer Hospital
Prof. Graham Pawelec, Department of Immunology, University of Tübingen, Tübingen, Germany
Head of Conference Secretariat, Dr. Vasiliki Gkioka
Research Themes Health and Health Inequalities
Projects Development of a cell line that represents early stage ovarian cancer
Org Units Centre for Biomedicine
URL https://scep.gr/en/events/event/pivac2023/

Guest Editor of the Special Issue on 'Molecular Mechanisms underlying, and Therapies targeting, Acute Myeloid Leukaemia II' in International Journal of Molecular Sciences
2022 - 2022

Org Units Centre for Biomedicine

Grant review for World Cancer Research Fund International
2022 - 2022

Description Reviewed a grant for World Cancer Research Fund International
Affiliated Organisations University of Hull
Org Units Centre for Biomedicine
URL www.wcrf.org

Grant reviewer for Leukaemia UK
2022 - 2022

Affiliated Organisations University of Hull

Guest Editor of the Special Issue on 'Molecular Mechanisms underlying, and Therapies targeting, Acute Myeloid Leukaemia' in International Journal of Molecular Sciences
2021 - 2021

Description Acute myeloid leukaemia (AML) is the second most frequent haematological malignancy in the paediatric population and remains a leading cause of childhood cancer mortality. In adults AML is rare, increasing in incidence with age, but it is still the most common form of acute leukaemia. Paediatric AML is viewed as a separate disease to adult AML, thought to occur due to single genetic changes that alone are enough to cause AML at a young age. In adults it is thought a lifetime accumulation of genetic alterations leads to the development of disease in later life. In both patient groups, and despite improvements to patient outcomes and associated overall survival (OS) rates they offer, current therapies still have limitations. It is essential, therefore, that we continue to identify new targets for therapy so that we can widen the scope of future treatments and determine their relevance to paediatric and adult leukaemias.
This special issue will focus on the identification and characterisation of the molecular mechanisms that underlie AML pathogenesis and new targets for the therapy of this rare and heterogenous disease. The aim is to review the state-of-the-art and look beyond current therapies to see where the future of AML treatment may reside.
For more details see https://www.mdpi.com/journal/ijms/special_issues/Molecular_Myeloid
Affiliated Organisations University of Hull
Org Units Centre for Biomedicine
URL https://www.mdpi.com/journal/ijms/special_issues/Molecular_Myeloid